Buying Direct From a 503A Pharmacy vs a Sourcing Partner
A 503A pharmacy compounds and dispenses under its state board. A sourcing partner holds the pharmacy relationship for you and runs procurement on your behalf. The practical difference for a clinic is not quality, it is leverage and effort: buying direct means negotiating each pharmacy yourself, and a partner means one relationship negotiated once. Neither model publishes much. Of the 15 suppliers we track across both, 2 publish a price you can read before making contact.
What each model actually is
Direct from a 503A pharmacy
You hold an account with the pharmacy that compounds your prescriptions. You deal with its formulary, its state licensing, its turnaround and its pricing, and you repeat that work for every pharmacy you add. In exchange you own the relationship and there is nobody between you and the people making the preparation.
Through a sourcing partner
One commercial relationship covers one or more pharmacies. The partner negotiates rates, handles onboarding and usually supplies the ordering software. You gain buying leverage you would not have alone and lose a degree of directness: the compounding is done by a pharmacy you did not contract with.
What a clinic can check before making contact
This is where the two models differ most, and not in the direction most clinics expect. Across 15 suppliers, 2 publish a price on a public page. Everything else is a provider account, a demo, or a quote after a prescription review. So the first question is not which model is cheaper, it is which suppliers will tell you anything at all before you have committed time to them.
Our pricing transparency index records what each one discloses, with the page it was read from and the date.
Does one model get a better price?
We cannot answer this from published data, and it would be dishonest to pretend otherwise: almost nobody in this market publishes clinic rates, so there is no dataset to compare. What can be said is structural. A partner aggregates volume across many clinics and negotiates against it, which is leverage a single med spa does not have. Buying direct removes a margin but also removes that leverage. Which wins depends on your volume, and the only way to find out is to have both quote you.
Switching supplier without disrupting patients
The switch itself is usually the reason a clinic stays somewhere it has outgrown. Three things decide whether it is disruptive.
- Licensing in your state. A supplier that cannot dispense where you practise cannot serve you at any price, and coverage varies far more than clinics expect. Confirm it before anything else.
- Overlap, not a cutover. Keep the existing account open until the new one has filled repeat orders at the strengths you actually use. A switch that strands a patient mid-titration is not a saving.
- Turnaround in writing. Ask what happens on a delay, not just what the normal lead time is. Most of this market publishes no fulfilment time at all, which makes the written answer the only one you have.
Which model suits which clinic
- Low or irregular volume: direct is usually simpler. There is little leverage to aggregate, and one pharmacy account is less to manage than a commercial agreement.
- Steady repeat volume: a partner has more to offer, because negotiated rates and a single ordering system are worth most when you are placing the same orders every month.
- Operating across several states: check coverage first either way. This is the constraint that most often decides it, and it has nothing to do with price.
- You want to inspect a price today: the transparency index shows who will let you.
Compiled from each supplier’s own published pages; counts are computed from the index and register rather than written by hand. Nothing here is medical advice or a recommendation to prescribe. Compounded medications are not FDA-approved.